Table 2.
Group characteristics | Frequency |
---|---|
Bone marrow involvement | 3 (17%) |
Lymph nodes enlargement > 2 cm | 6 (33%) |
2–4 prior chemotherapy regimens | 6 (33%) |
Previous treatment with rituximab | 12 (67%) |
Group characteristics | Frequency |
---|---|
Bone marrow involvement | 3 (17%) |
Lymph nodes enlargement > 2 cm | 6 (33%) |
2–4 prior chemotherapy regimens | 6 (33%) |
Previous treatment with rituximab | 12 (67%) |